Company: LHI
Filing Date: 2025-11-20
Form Type: F-1/A
Source: 0001213900-25-112807
Chunk: 119

Company: Living Homeopathy International Ltd.
Filing Date: 2025-11-20
Form: F-1/A
Chunk 119
---
generated from operating activities was $1,463,328, which was primarily derived from (i) net income of $812,130 and adjusted for non-cash
depreciation of $36,052; (ii) decrease in inventories by $339,871 as the Company realize the value of the inventories during the year;
(iii) increase in accrued expenses and other payables by $366,186 for the IPO related expenses; (iv) increase in account payables by
$4,306 as the payment have yet due as of March 31, 2025; while partially offset by (i) increase in prepayments to suppliers by $182,086
as the suppliers have yet to delivered the goods that the we have paid.

For the year ended March 31, 2024, our net cash
generated from operating activities was $687,495, which was primarily derived from (i) net income of $753,429 and adjusted for non-cash
depreciation of $86,321; (ii) decrease in prepayment to suppliers by $149,211 as products ordered has delivered during the year; while
partially offset by (i) increase in inventories by $225,073 as we intended to hold higher inventories to support promotional activities
aimed at stimulating sales during the downturn; (ii) decrease in tax payable by $110,319 as provisional tax paid was estimated according
to net assessable profit of fiscal year 2023 which was higher than current income tax expense incurred for the fiscal year 2024.

Net cash used in financing activities

Net cash used in financing activities was $1,299,123
for the year ended March 31, 2025, which primarily resulted from repayment of $232,737, to Hang Seng Bank Limited in accordance with
the property installment loan agreement between Living Homeopathy Limited and Hang Seng Bank Limited dated October 20, 2021 (the “Hang
Seng Mortgage Loans”); (ii) advances of $981,903 to Mr. To, our Chairman and Chief Executive Officer; (iii) increase in deferred
offering costs by $1,007,167 for the IPO related expenses; and offset by the increase of advance from related party by $924,241 by Ms.
Hung, one of our shareholders which mainly to finance us for the IPO related expenses.

Net cash used in financing activities was $574,414
for the year ended March 31,